{"id":"metformin-and-mitiglinide","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"},{"rate":"<1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":{"chemblId":"CHEMBL471498","moleculeType":"Small molecule","molecularWeight":"315.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and increases peripheral glucose uptake and utilization. Mitiglinide is a meglitinide that binds to ATP-sensitive potassium channels on pancreatic beta cells, triggering rapid insulin secretion. Together, they address both insulin resistance and beta cell dysfunction in type 2 diabetes.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while mitiglinide stimulates pancreatic beta cells to release insulin in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:29.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT02503943","phase":"PHASE4","title":"Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital of Third Military Medical University","startDate":"2015-05","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":90},{"nctId":"NCT01443221","phase":"PHASE1","title":"Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2010-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT01037842","phase":"PHASE3","title":"Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-08","conditions":"Type 2 Diabetes","enrollment":145},{"nctId":"NCT00519142","phase":"PHASE3","title":"Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Elixir Pharmaceuticals","startDate":"2007-08","conditions":"Diabetes Mellitus, Type 2","enrollment":367}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20100917","type":"ORIG","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20140103","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"20200820","type":"SUPPL","sponsor":"CHARTWELL RX","applicationNumber":"ANDA079025"},{"date":"19990406","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19810828","type":"ORIG","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20001128","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19880726","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"19830516","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20000403","type":"SUPPL","sponsor":"FOSUN PHARMA","applicationNumber":"ANDA086173"},{"date":"20111221","type":"ORIG","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20150902","type":"SUPPL","sponsor":"HOSPIRA INC","applicationNumber":"ANDA090653"},{"date":"20120626","type":"ORIG","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150518","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20150903","type":"SUPPL","sponsor":"PADAGIS ISRAEL","applicationNumber":"ANDA090979"},{"date":"20250620","type":"SUPPL","sponsor":"XIROMED","applicationNumber":"ANDA206120"},{"date":"20170912","type":"ORIG","sponsor":"XIROMED","applicationNumber":"ANDA206120"}],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"\"Metformin\" and \"Mitiglinide\"","genericName":"\"Metformin\" and \"Mitiglinide\"","companyName":"Third Affiliated Hospital of Third Military Medical University","companyId":"third-affiliated-hospital-of-third-military-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while mitiglinide stimulates pancreatic beta cells to release insulin in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}